Proof of Concept


proof of concept trials

ARENSIA delivers high degree of scientific and logistical expertise for Phase I/Ib/IIa and PROOF OF CONCEPT patient studies.



phase i special populations

ARENSIA offers exceptional fast recruitment rates for renal and hepatic impaired patients.



regulatory process

ARENSIA has the know-how to successfully manage the regulatory process in various Eastern European countries.



Pharmaceutical and Biotechnology companies are increasingly required to gather concise knowledge on the characteristics of a given compound with fewer clinical trials at a much early stage. This is to reduce the time taken to decide on the continuation on the development strategy.  This is fundamental for both the scientific and economic justifications.

Every year the exploratory clinical trials - be they in healthy volunteers or patients - have become more and more complex. There is a greater level of design complexity and end points with larger sample sizes.

ARENSIA offers:

  • Dedicated highly experienced team with exceptional reputation in performing sophisticated First-into-Patient trials
  • A unique model of state-of-the-art research clinics in Eastern Europe, specialized in performing Phase Ib/IIa/POC clinical trials, with proven fast industry beating patient recruitment achievements/capabilities
  • Tailored Regulatory Strategies

These approaches have greatly benefited our Sponsors as we have reduced timelines, and required resources considerably, facilitating the acceleration to PROOF OF CONCEPT.

ARENSIA has further reduced time to PROOF OF CONCEPT by using a compact regulatory strategy. This is achieved by using “integrated” protocols. Specifically, by coordinating the activities for First-in-Man studies in healthy volunteers - typically performed by CROs in Western Europe or the US - with First-in-Patient studies performed at ARENSIA´s research clinics in Eastern Europe.

ARENSIA has successfully contributed to numerous “integrated” protocols in immunology, dermatology, gastroenterology and infectious diseases, for both large pharmaceutical companies and small biotechnology companies.

From established study concepts ARENSIA will help to create a tailored strategy.  ARENSIA can provide fully costed timelines that can include or exclude the “integrated protocol” model.


We use technologies, such as cookies, and process personal data, such as IP addresses and cookie identifiers, to personalise content based on your interests, measure the performance of our content, and derive insights about the audiences who saw it. You can read more about our Cookie Policy here.

I accept I refuse